{
  "1": {
    "premise": "78-year-old patient with stage IV HER2-positive breast cancer receiving daily paclitaxel at 315 mg/m² for 12 weeks, along with standard trastuzumab therapy (initial loading dose of 4 mg/kg followed by 2 mg/kg weekly for 12 weeks, then 6 mg/kg every 3 weeks for 40 weeks).",
    "statement": "The patient is expected to experience clinical benefit from their treatment regimen, leading to disease stabilization and improved overall prognosis.",
    "label": "contradiction",
    "responses": [
      "output: neutral",
      "The premise describes the patient’s diagnosis and treatment regimen but says nothing about the expected clinical benefit or prognosis. Therefore, the statement is neither supported nor contradicted by the premise.\n\noutput: neutral",
      "The premise provides information about the patient’s diagnosis and treatment protocol but does not mention any expected clinical benefit, disease stabilization, or prognosis. Therefore, the statement is not entailed by the premise, nor is it contradicted. \n\noutput: neutral",
      "The premise only describes the patient’s diagnosis and treatment regimen; it gives no information about expected clinical benefit, disease stabilization, or prognosis. Therefore, the statement cannot be affirmed or denied based solely on the premise.  \noutput: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral"
    ]
  },
  "2": {
    "premise": "65-year-old male with non-Hodgkin lymphoma receiving cyclophosphamide at 415mg/m² intravenously on Days 1–5 of each 21-day cycle, for 4 cycles.",
    "statement": "The treatment is expected to result in some reduction in lymph node size, with durable response and extended survival.",
    "label": "contradiction",
    "responses": [
      "The premise only specifies the patient’s diagnosis and the chemotherapy regimen; it does not provide any information about anticipated efficacy, lymph node reduction, durability of response, or survival. Therefore, the statement introduces new information that is not supported or refuted by the premise. \n\noutput: neutral",
      "output: neutral",
      "The premise describes a patient and the chemotherapy regimen being given but does not mention any expected outcomes such as reduction in lymph node size, durable response, or extended survival. The statement introduces new information not present in the premise and not contradicted by it.\n\noutput: neutral",
      "output: neutral",
      "The premise describes the patient’s diagnosis and chemotherapy regimen but provides no information about expected clinical outcomes such as lymph-node shrinkage, durability of response, or survival. Therefore, the statement’s claims about expected reductions in lymph node size and extended survival are neither supported nor contradicted by the premise.\n\noutput: neutral",
      "output: neutral",
      "output: neutral",
      "Based on the premise alone, there is no explicit information about treatment outcomes such as reduction in lymph-node size, durability of response, or overall survival. Therefore, the statement cannot be inferred, nor is it contradicted by the given information.\n\noutput: neutral",
      "output: neutral",
      "output: neutral"
    ]
  },
  "3": {
    "premise": "68-year-old female with type 2 diabetes and chronic kidney disease (eGFR 25 mL/min/1.73m²) receiving metformin 1000mg twice daily.",
    "statement": "The treatment is expected to improve glycemic control, reduce cardiovascular risk, and provide long-term kidney protection.",
    "label": "contradiction",
    "responses": [
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral"
    ]
  },
  "4": {
    "premise": "45‑year‑old patient with squamous cell carcinoma receiving weekly cetuximab at 250mg/m² and cisplatin at 250mg/m² daily for 7 days.",
    "statement": "The patient is expected to show partial regression of the tumor, with a favorable clinical response and improved progression-free survival.",
    "label": "contradiction",
    "responses": [
      "output: neutral",
      "output: neutral",
      "The premise provides information on the patient’s diagnosis and the treatment regimen being administered. It does not state anything about tumor regression, clinical response, or progression-free survival outcomes. Therefore, the statement’s claims about expected tumor regression and improved outcomes are not supported or contradicted by the premise.\n\noutput: neutral",
      "The premise only describes the patient’s diagnosis and treatment regimen; it does not mention any expected tumor regression, clinical response, or progression-free survival. Therefore, the statement is not supported or contradicted by the premise.\n\noutput: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "The premise only specifies the patient’s diagnosis and treatment regimen; it gives no information about treatment outcomes such as tumor regression, clinical response, or progression-free survival. Therefore, the stated expectation cannot be inferred from the premise alone, nor is it contradicted.\n\noutput: neutral",
      "output: neutral",
      "The premise only states the patient’s diagnosis and chemotherapy regimen. It gives no information about expected tumor regression, clinical response, or progression-free survival. Therefore, the statement is neither entailed nor contradicted by the premise.  \n\noutput: neutral"
    ]
  },
  "5": {
    "premise": "72-year-old patient with advanced non-small cell lung cancer receiving cisplatin at 120mg/m² on Day 1 and vinorelbine 30mg/m² on Days 1 and 8 of a 21-day cycle, repeated for 6 cycles.",
    "statement": "The patient is expected to experience tumor response with improved respiratory function and overall clinical benefit.",
    "label": "contradiction",
    "responses": [
      "The premise only provides information about the patient’s diagnosis and chemotherapy regimen; it does not mention any expected outcomes or clinical benefits. Therefore, the statement about expected tumor response and improved respiratory function is not supported or contradicted by the premise.\n\noutput: neutral",
      "The premise only describes the patient’s diagnosis and chemotherapy regimen. It does not mention any expectations or outcomes such as tumor response, improved respiratory function, or overall clinical benefit. Therefore, we cannot conclude the statement from the premise, nor is it contradicted. \n\noutput: neutral",
      "output: neutral",
      "output: neutral",
      "The premise lists the patient’s diagnosis and chemotherapy regimen but does not state anything about the expected outcomes (tumor response, improved respiratory function, or overall clinical benefit). Therefore, the statement is not entailed nor contradicted by the premise; it presents additional information that could be true but is not asserted in the premise.\n\noutput: neutral",
      "output: neutral",
      "The premise only describes the patient’s diagnosis (advanced non-small cell lung cancer) and the chemotherapy regimen being administered. It provides no information about expected treatment outcomes such as tumor response, improved respiratory function, or overall clinical benefit. Therefore, the statement introduces new information not supported or contradicted by the premise.\n\noutput: neutral",
      "output: neutral",
      "The premise only describes the patient’s diagnosis and chemotherapy regimen; it gives no information about expected tumor response, respiratory function, or overall clinical benefit. Therefore, the statement cannot be inferred nor contradicted from the premise alone.\n\noutput: neutral",
      "output: neutral"
    ]
  },
  "6": {
    "premise": "53-year-old female with triple-negative breast cancer receiving doxorubicin 90mg/m² every week for 8 weeks.",
    "statement": "The patient is expected to respond well to the regimen, with meaningful tumor shrinkage and sustained clinical benefit.",
    "label": "contradiction",
    "responses": [
      "output: neutral",
      "output: neutral",
      "The premise only states the patient’s diagnosis and treatment regimen; it gives no information about predicted effectiveness or clinical outcomes. Therefore, the statement about expected tumor shrinkage and sustained benefit is not supported or contradicted by the premise. \n\noutput: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "The premise only reports the patient’s diagnosis and treatment regimen and makes no claim about expected efficacy. The statement introduces new information (expected response and benefits) not present in the premise and not contradicted by it. Therefore, the relationship is neutral.\n\noutput: neutral",
      "output: neutral",
      "output: neutral"
    ]
  },
  "7": {
    "premise": "2-month-old infant diagnosed with metastatic melanoma receiving pembrolizumab 200mg intravenously every 3 weeks.",
    "statement": "The therapy is expected to induce an immune response against the tumor and improve the clinical outlook.",
    "label": "contradiction",
    "responses": [
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "The premise only states that the infant is receiving pembrolizumab. It does not say anything about expected immune responses or clinical improvement. The statement therefore introduces new information that is not present in the premise, without conflicting with it. \n\noutput: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral"
    ]
  },
  "8": {
    "premise": "59-year-old male with relapsed acute lymphoblastic leukemia receiving methotrexate 250mg/m² intravenously daily for 10 consecutive days.",
    "statement": "The treatment is expected to reduce leukemic burden and improve survival prospects.",
    "label": "contradiction",
    "responses": [
      "output: neutral",
      "output: neutral",
      "The premise only states that a patient is receiving methotrexate; it gives no information about the expected outcomes of that treatment. Therefore, the statement about reducing leukemic burden and improving survival is not supported or contradicted by the premise. \n\noutput: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral"
    ]
  },
  "9": {
    "premise": "64-year-old patient with advanced pancreatic cancer receiving gemcitabine 1250mg/m² intravenously on Days 1–5 every 21 days for four cycles.",
    "statement": "The treatment is expected to relieve symptoms and prolong overall survival.",
    "label": "contradiction",
    "responses": [
      "The premise only specifies the patient’s diagnosis and chemotherapy regimen; it says nothing about the anticipated effects of that treatment. Therefore, the statement’s claim regarding symptom relief and prolonged survival is not supported or contradicted by the premise. \n\noutput: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "The premise only provides information about the patient’s diagnosis and dosing regimen; it does not say anything about the expected effects on symptoms or survival. Therefore, the statement is neither supported nor contradicted by the premise. \n\noutput: neutral",
      "output: neutral",
      "The premise only describes the patient’s diagnosis and the chemotherapy regimen (gemcitabine 1250 mg/m² on Days 1–5 every 21 days for four cycles). It says nothing about the anticipated effects on symptoms or survival. Therefore, the statement is not entailed, nor is it contradicted; it is simply not supported by the information given.\n\noutput: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral"
    ]
  },
  "10": {
    "premise": "60-year-old male with head and neck squamous cell carcinoma receiving cisplatin 250mg/m² daily for 7 consecutive days along with standard radiation therapy.",
    "statement": "The regimen is expected to enhance tumor control and improve survival outcomes.",
    "label": "contradiction",
    "responses": [
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "output: neutral",
      "The premise merely describes the patient’s treatment regimen but makes no claim about its expected effects on tumor control or survival. Therefore, the statement cannot be inferred as true or false from the given information.\n\noutput: neutral",
      "output: neutral",
      "The premise only describes the patient’s current treatment regimen; it does not provide any information about whether this regimen is expected to enhance tumor control or improve survival outcomes. Therefore, the statement’s claim is neither supported nor contradicted by the premise.\n\noutput: neutral",
      "output: neutral"
    ]
  }
}